Veru Inc.
$2.41
$0.02 (+0.84%)
$2.36Day Range$2.44
Key Statistics
Market Cap
$41.09M
Shares Outstanding
17.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 1, 1990
Round Lot
100
Locale
US
Trading Data
Day Open
$2.39
Day High
$2.44
Day Low
$2.36
Volume
103.0K
VWAP
$2.40
Prev Close
$2.39
Transactions
--
Acc. Volume
--
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
PHARMACEUTICAL PREPARATIONSSIC 283420 employees2916 N. MIAMI AVENUE, MIAMI, FL, 33127(312) 595-9123IPO Jun 1, 1990US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000863894
- Composite FIGI
- BBG000G12J78
- Share Class FIGI
- BBG001SCF2T8
- Ticker Root
- VERU
- SIC Code
- 2834
About Veru Inc. (VERU) Stock
Veru Inc. (VERU) closed the 2026-09-18 session at $2.41, up 0.84% versus the previous close (+0.02). The stock opened at $2.39 and traded between $2.36 and $2.44 during that session. Session trading volume was 103K shares. The volume-weighted average price (VWAP) is $2.40.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Veru Inc. has a market capitalization of $41.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VERU is listed on the XNAS exchange. The company employs approximately 20 people. Veru Inc. is headquartered in MIAMI, FL. The recorded listing date is 1990-06-01.
On this page you can find market VERU stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.